Tuesday, October 13, 2020 4:17:41 PM
The great English Lexicographer and father of the English Dictionary Samuel Johnson was reported as saying:
"The law is the last result of human wisdom acting upon human experience for the benefit of the public."
In fact and in evidence that is not the case today. Boswell who was Johnson's biographer and an attorney himself said: "As to precedents, to be sure they will increase in course of time; but the more precedents there are, the less occasion is there for law; that is to say, the less occasion is there for investigating principles."
We have on this board pointed out that the numerous scientific misrepresentations of one Jay W Heinecke (hiding behind the claim construction order of Judge Du which, he says gives him the right to say black is white and vice-versa). We have pointed out that Mori was misreprespresented in what it showed vis-a-vis LDL-EPA, and this was confirmed in Nature Biotechnology by amongst other eminent POSA's, the lead investigator of the REDUCE-IT trial, Dr Deepak Bhatt. This was apparently insufficient. We then clearly demonstrated that Dr. Heinecke perjured himself (at least scientifically if not legally), by insisiting on an utterly false statistical construction of what EPA effect on ApoB evidenced in Table 3 of the Kurabayashi paper. The central reason for the allowance of the MARINE patents was in fact the unexpected result and long felt unmet need of the singular ApoB effect of EPA in TG>500 patients. We further showed evidence that when asked HOW to interpret the self same data he admitted in sworn deposition that he relies on an intergroup statistic for comparison that he then shamefully abandons this standard in discussing ApoB for the Defendant's convenience.
But here is the last sting in this sordid tale: The entire construct for dismissing all this evidence was that Judge Du felt that Kurabayashi was not considered by the patent examiner and that furthermore the ApoB effects of EPA were obviously evident, and therefore (along with MORI) cause for negation of the MARINE patents. Here, we show that INFACT the self same "significant" effect of EPA on ApoB is in fact not p less than 0.001 as rperesented in teh Table 3, but actually p=0.11 and ipso facto, that the entire ApoB analysis by Heinecke and (coincidentally by Kurabayashi et al.)is in fact WRONG. There was NO significance in the EPA ApoB effect and there was NO effect in the control arm and further that when the two groups were appropriately compared using a Two way ANOVA OR even using intergroup unpaired t-tests there was NON-SIGNIFICANCE.
Is this just a raging storm in a teacup in the inevitable legal "battle between experts". Maybe? But was this debate of the scientific experts properly conducted, and more importantly was the scientific evidence properly represented? We humbly submit otherwise...
HK on behalf of EPADI II
Here is the evidence that shows that Kurabayshi showed nothing in regard to EPA and ApoB (for those who actually care about details):
https://investorshub.advfn.com/uimage/uploads/2020/10/13/gawrxkurabayshi_latest_analysis_ApoB_10_13-2020.png
Recent AMRN News
- Amarin Announces Two Upcoming Investor Events • GlobeNewswire Inc. • 10/01/2024 12:00:00 PM
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 09:30:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:05:26 AM
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:30:08 PM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
FEATURED CBD Life Sciences, Inc. (CBDL) Reaches Unprecedented Heights With Explosive Growth and Strategic Expansion in 2024 • Oct 8, 2024 8:00 AM
BNCM COMPLETES MERGER WITH DELEX HEALTHCARE • BNCM • Oct 8, 2024 9:54 AM
Unitronix Corp. to Invest $3 Million in USA Unity Coin Project • UTRX • Oct 7, 2024 7:08 AM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM